Xeris Biopharma Holdings (XERS) closed at $16.66 on November 13, 2026, up 0.1% from the previous close, on volume of 2,811,460 shares (30-day average 2,917,057).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Calendar Call Spread | 16-Oct : 20-Nov-26 10 C | 684 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Barclays Keeps Their Buy Rating on Xeris Pharmaceuticals (XERS)
TipRanks (Wed, 11-Nov 4:16 AM ET)
Xeris lifts 2030 revenue outlook to more than $1 billion as Recorlev grows 93% year-over-year
Market Chameleon (Thu, 5-Nov 2:51 AM ET)
Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Business Wire (Thu, 5-Nov 7:00 AM ET)
Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
Business Wire (Mon, 2-Nov 8:00 AM ET)
Business Wire (Thu, 22-Oct 8:00 AM ET)
Business Wire (Thu, 15-Oct 8:00 AM ET)
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire (Fri, 2-Oct 5:00 PM ET)
Business Wire (Wed, 9-Sep 8:30 AM ET)
Xeris Announces Details for XP-8121 Program Overview Webinar
Business Wire (Wed, 26-Aug 7:30 AM ET)
Market Chameleon (Fri, 12-Jun 6:30 AM ET)
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Xeris Biopharma Holdings trades on the NASDAQ stock market under the symbol XERS.
As of November 13, 2026, XERS stock price climbed to $16.66 with 2,811,460 million shares trading.
XERS has a beta of 0.77, meaning it tends to be less sensitive to market movements. XERS has a correlation of 0.02 to the broad based SPY ETF.
XERS has a market cap of $3.04 billion. This is considered a Mid Cap stock.
Last quarter Xeris Biopharma Holdings reported $106 million in Revenue and $.06 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.03.
In the last 3 years, XERS traded as high as $16.88 and as low as $1.46.
The top ETF exchange traded funds that XERS belongs to (by Net Assets): IWM, VTI, IWO, XPH, VXF.
XERS has outperformed the market in the last year with a price return of +129.5% while the SPY ETF gained +13.4%. XERS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +100.0% and +55.6%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
XERS support price is $16.00 and resistance is $17.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XERS shares will trade within this expected range on the day.
